Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 23, 2016. The report disseminates a press release from ViiV Healthcare, a global specialist HIV company majority-owned by GSK (with Pfizer Inc. and Shionogi Limited as shareholders). The filing details positive results from the LATTE-2 Phase IIb study regarding a long-acting injectable HIV-1 treatment regimen.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is a clinical update rather than a financial earnings report.
Material Changes and Clinical Results
The primary material update concerns the LATTE-2 study results presented at the Conference on Retroviruses and Opportunistic Infections (CROI). Key findings include:
- Viral Suppression: After 32 weeks of maintenance treatment, viral suppression rates for the two-drug injectable regimen were comparable to the three-drug oral regimen. Rates were 95% for the eight-week dosing group, 94% for the four-week dosing group, and 91% for the oral regimen group.
- Study Design: The study involved 309 HIV-infected adults who achieved viral suppression during a 20-week induction period. Patients were randomized to injectable cabotegravir plus rilpivirine (every 4 or 8 weeks) or continued oral therapy.
- Adverse Events: The most common drug-related adverse event for the injectable group was injection site pain (92%), mostly mild (82%) or moderate (17%). Serious adverse events occurred in 6% of injectable patients and 5% of oral patients.
- Failures and Withdrawals: One patient in the eight-week group and one in the oral group met virologic failure criteria without evidence of resistance. Nine patients withdrew due to adverse events. One patient in the eight-week group died due to a seizure unrelated to the study drug.
Guidance, Outlook, and Risks
Outlook: Management indicated an aim to commence Phase III studies for the long-acting injectable regimen in 2016. The study is ongoing and will continue up to 104 weeks of treatment.
Risks and Contingencies:
- Safety Profile: Risks include injection site pain, nasopharyngitis, headache, and diarrhea. Serious adverse events and lab abnormalities (Grade 3 severity) were observed in both treatment arms.
- Drug Interactions: The filing includes extensive safety information regarding EDURANT (rilpivirine), noting interactions with anti-seizure medicines, anti-TB medicines, proton pump inhibitors, and St. John's wort.
- Side Effects: Potential serious side effects include severe skin rash, allergic reactions, depression, liver problems, and immune reconstitution syndrome.
Investor Verification Checklist
- Verify the timeline and design of the upcoming Phase III studies for cabotegravir and rilpivirine.
- Monitor long-term safety data as the LATTE-2 study extends to 104 weeks.
- Assess the commercial potential of a two-drug injectable regimen versus existing three-drug oral therapies.
- Review regulatory pathways for approval of long-acting injectable HIV treatments in key markets.
- Confirm the ownership structure and financial contribution of ViiV Healthcare to GSK's overall portfolio.